Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Non Operating Income (2020 - 2025)

Xeris Biopharma Holdings' Other Non Operating Income history spans 6 years, with the latest figure at $18.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income rose 374.59% year-over-year to $18.6 million, compared with a TTM value of -$25.4 million through Sep 2025, down 30.7%, and an annual FY2024 reading of -$23.5 million, down 20.33% over the prior year.
  • Other Non Operating Income for Q4 2025 was $18.6 million at Xeris Biopharma Holdings, up from -$6.1 million in the prior quarter.
  • The five-year high for Other Non Operating Income was $18.6 million in Q4 2025, with the low at -$7.6 million in Q3 2023.
  • Average Other Non Operating Income over 5 years is -$2.8 million, with a median of -$4.5 million recorded in 2023.
  • Year-over-year, Other Non Operating Income crashed 340.28% in 2022 and then surged 374.59% in 2025.
  • Tracing XERS's Other Non Operating Income over 5 years: stood at $5.0 million in 2021, then plummeted by 62.34% to $1.9 million in 2022, then crashed by 247.21% to -$2.8 million in 2023, then plummeted by 142.57% to -$6.8 million in 2024, then surged by 374.59% to $18.6 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Other Non Operating Income are $18.6 million (Q4 2025), -$6.1 million (Q3 2025), and -$6.4 million (Q2 2025).